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Abstract
Human pancreatic ribonuclease (RNase 1) is a small secretory protein that catalyzes the cleavage of RNA. This highly
cationic enzyme can enter human cells spontaneously but is removed rapidly from circulation by glomerular filtration.
Here, this shortcoming is addressed by attaching a poly(ethylene glycol) (PEG) moiety to RNase 1. The pendant has
no effect on ribonucleolytic activity but does increase persistence in circulation. The RNase 1–PEG conjugates inhibit
the growth of tumors in a xenograft mouse model of human lung cancer. Both retention in circulation and tumor
growth inhibition correlate with the size of the pendant PEG. A weekly dose of the 60-kDa conjugate at 1 μmol/kg
inhibited nearly all tumor growth without affecting body weight. Its molecular efficacy is∼5000-fold greater than that
of erlotinib, which is a small molecule in clinical use for the treatment of lung cancer. These data demonstrate that
the addition of a PEG moiety can enhance the in vivo efficacy of human proteins that act within cells and highlight a
simple means of converting an endogenous human enzyme into a cytotoxin with potential clinical utility.
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Introduction
An impediment to the development of proteins as chemotherapeutic
agents is the dearth of human proteins that can act as cytotoxins. One
exception is human pancreatic ribonuclease (RNase 1) [1–3]. Like
RNase A (which is its storied bovine homolog [4–6]), RNase 1 catalyzes
the cleavage of single-stranded RNA after pyrimidine residues. As a
highly cationic protein, RNase 1 can enter the cytosol of human cells
spontaneously and there manifest cytotoxic ribonucleolytic activity
[7–9]. As a small protein, RNase 1 is cleared rapidly from circulation
through glomerular filtration [10,11]. A simple variant of RNase 1 is
now in a phase 1 clinical trial as a cancer chemotherapeutic agent
[12], and we reasoned that the installation of a poly(ethylene glycol)
(PEG) moiety could enhance the utility of RNase 1 by increasing its
persistence in circulation [13–15].
RNase 1 has no free cysteine residues. Hence, site-directed muta-
genesis can be used to install a unique sulfhydryl group that could
be linked to a PEG moiety. Because RNase 1 has 128 residues, the
ensuing PEGylated enzyme would be >99% identical in amino acid
sequence to an endogenous human protein. Previously, various aspects
of this semisynthetic strategy have shown promise with other ribo-
nucleases and nucleases from plants [16–18] and animals [19–22].
Deleterious immunologic responses could, however, compromise the
utility of these foreign proteins in the clinic. Accordingly, we sought
to validate the strategy with a human enzyme.
Herein, we report on the preclinical attributes of site-specific PEG
conjugates to RNase 1. Despite their low cytotoxic activity in vitro,
we find that these conjugates are highly efficacious in inhibiting
the growth of tumors in xenograft mouse models. This work opens
a new frontier in the development of anticancer drugs based on
human proteins.
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Materials and Methods
Materials
Escherichia coli BL21(DE3) cells and pET22b(+) plasmid were from
Novagen (Madison, WI). Cell lines K-562 (human chronic myelo-
genous leukemia) and A549 (human alveolar adenocarcinoma) were
from the American Type Culture Collection (Manassas, VA). Homo-
zygous male athymic (nu/nu) mice were from Harlan Laboratories
(Indianapolis, IN). Cell culture medium and supplements [including
Dulbecco’s phosphate-buffered saline (PBS)] were from Invitrogen
(Carlsbad, CA).
Erlotinib hydrochloride (Tarceva) was from Genentech (South
San Francisco, CA). [Methyl-3H]thymidine (6.7 Ci/mmol) was from
PerkinElmer (Boston, MA). RNase 1 substrate 6-FAM-dArUdAdA-
6-TAMRA was from Integrated DNA Technologies (Coralville, IA).
Both linear mPEG-maleimide (5 and 20 kDa; 1 and 2) and branched
mPEG2-maleimide (60 kDa; 3; Figure 1A) were from Nektar Thera-
peutics (Huntsville, AL). Chromatography columns and resins were
from GE Healthcare (Uppsala, Sweden). Gel filtration standards, so-
dium dodecyl sulfate–polyacrylamide gel electrophoresis molecular
weight standards, and precast gels for poly(acrylamide) electrophoresis
were from BioRad (Hercules, CA). The BCA protein assay kit was from
Pierce (Rockford, IL). Black nontreated 96-well plates for pharmaco-
kinetic assays were from NUNC (Rochester, NY). All other chemicals
used were of commercial reagent grade or better and were used without
further purification.
Analytical Instruments
The mass of purified proteins was confirmed by matrix-assisted laser
desorption ionization–time of flight (MALDI-TOF) mass spectrometry
using a Voyager-DE-PRO Biospectrometry Workstation from Applied
Biosystems (Foster City, CA) in the campus Biophysics Instrumentation
Facility. Cuvette-scale fluorescence measurements were made using a
QuantaMasterl photon-counting fluorometer equipped with sample
stirring from Photon Technology International (South Brunswick, NJ).
[Methyl-3H]thymidine incorporation into genomic DNA was quan-
titated by scintillation counting using a Microbeta TriLux liquid scintil-
lation and luminescence counter from PerkinElmer (Wellesley, MA).
Production of Proteins
Previously, a cysteine residue was installed in place of Gly89 of
RNase 1 [23]. The unique sulfhydryl group of this G89C variant
was used to construct conjugates with transferrin that had desirable
attributes in vitro. Accordingly, G89C RNase 1 was employed for
the attachment of PEG chains herein.
DNA encoding G89C RNase 1 was created by oligonucleotide-
mediated site-directed mutagenesis using a pET22b(+) plasmid that
contained cDNA encoding wild-type RNase 1 [11]. The G89C variant
of RNase 1 was produced in E. coli, the side chain of residue 89 was pro-
tected as a mixed disulfide with 2-nitro-5-thiobenzoic acid (NTB), and
the NTB-protected G89C RNase 1 was purified as described previously
[11]. Wild-type RNase 1, RNase A, and onconase (ONC; which is a
cytotoxic homolog of RNase 1 from the Northern leopard frog, Rana
pipiens [24]) were produced in E. coli and purified as described previously
[7,25]. The human ribonuclease inhibitor protein (RI) [26] (which is
a cytosolic protein with femtomolar affinity for RNase 1 [8]), was pro-
duced in E. coli and purified as described previously [27,28]. Following
purification, each ribonuclease and RI migrated as a single band during
sodium dodecyl sulfate–polyacrylamide gel electrophoresis.
Semisynthesis of RNase 1–PEG Conjugates
RNase 1–PEG conjugates were prepared by S-alkylation of Cys89 of
G89C RNase 1 with a maleimido PEG. The pH of the protein solu-
tion containing NTB-protected G89C RNase 1 in cation exchange
elution buffer was adjusted from 5 to 7.4–8.0 by the addition of
1.0 M Tris-HCl buffer (pH 7.8–8.0) to 20% (vol/vol). The protecting
group was removed by adding DTT (5 equiv) and allowing the reaction
to proceed for 2 to 5 minutes, resulting in the immediate generation of
the yellow TNB anion [29]. The ribonucleases were separated from
DTT, TNB, and salt by using a HiTrap desalting column equilibrated
with PBS. A 10-fold molar excess of maleimido PEGs 1, 2, or 3
(Figure 1A) was dissolved in an equivalent volume of PBS (relative to
the volume of ribonuclease-containing solution) and added to the
solution containing the deprotected ribonuclease (final [ribonuclease]:
∼200 μM). Alkylation reactions were allowed to proceed at room tem-
perature for ∼2 hours or overnight at 4°C. Any remaining maleimide
groups were quenched by the addition of DTT to a final concentra-
tion of 2 mM. To lessen the concentration of residual salt, reactions
were diluted to 50 ml with 50 mM sodium acetate buffer (pH 5.0)
and dialyzed overnight against 4 l of 50 mM sodium acetate buffer
(pH 5.0).
Figure 1. Structures of relevant molecules. (A) Maleimido PEGs used
for the preparation of RNase 1–PEG conjugates. (B) A model of the
complex between G89C RNase 1 and RI. The model was built
by replacing Gly89 in Protein Data Bank (PDB) entry 1z7x [8] with a
cysteine residue. The enzymatic active site and side chain of Cys89
are indicated explicitly.
Translational Oncology Vol. 6, No. 4, 2013 Human Ribonuclease Inhibits Tumor Growth in Mice Rutkoski et al. 393
The purification of RNase 1–PEG conjugates relied on the differen-
tial affinity for a cation exchange resin. The dialyzed reaction mixtures
were applied to a column of HiTrap SPHP cation exchange resin
equilibrated with the same buffer and eluted from the resin with a
linear gradient of NaCl (0–0.65 M) in 50 mM sodium acetate buffer
(pH 5.0). Purification of the highly shielded 60-kDa mPEG2–G89C
RNase 1 required dilution of the dialyzed reaction mixture to reduce
the salt concentration. RNase 1–PEG conjugates were purified further
by chromatography using HiLoad 26/60 G200 Superdex gel filtration
resin equilibrated with 50 mM sodium acetate buffer (pH 5.0) con-
taining NaCl (0.10 M) and NaN3 (0.05% wt/vol).
Analyses of RNase 1–PEG Conjugates In Vitro
Analytical size exclusion chromatography. The hydrodynamic
volume of the RNase 1–PEG conjugates was estimated with size
exclusion chromatography. A 1.0 mg/ml solution of a conjugate in
gel filtration buffer was applied to a HiLoad 26/60 Superdex G200
gel filtration column and eluted with 50 mM sodium acetate buffer
(pH 5.0) containing NaCl (0.10 M) and NaN3 (0.05% wt/vol) at
a flow rate of 4 ml/min. Gel filtration standards were prepared
and separated using the same column according to the guidelines
of the manufacturer.
Assays of catalytic activity. The ribonucleolytic activity of RNase 1–
PEG conjugates was determined by assaying their ability to cleave the
hypersensitive fluorogenic substrate 6-FAM-dArUdAdA-6-TAMRA
[30]. The MES used to prepare the assay buffer was purified by anion
exchange chromatography to remove trace amounts of oligomeric
vinylsulfonic acid, which is a by-product of commercial buffer synthesis
and a potent inhibitor of ribonucleolytic activity [31].
Assays of binding to the RI. The ability of human RI to bind to
RNase 1–PEG conjugates was determined by using a fluorescence-
based competition assay [28,32].
Assays of cytotoxicity. RNase 1–PEG conjugates were tested for
their ability to inhibit the in vitro proliferation of K-562 cells, which
are especially vulnerable to ribonuclease cytotoxins [33]. The assays
monitor the incorporation of [methyl-3H]thymidine into the cellular
DNA, which is lessened on apoptosis elicited by ribonucleases [34].
Onconase served as a positive control. All cytotoxicity assays were
performed at least three times. Half-maximal inhibitory concentration
(IC50) values were calculated by fitting the data to a sigmoidal dose-
response curve using nonlinear regression analysis [28].
Xenograft Studies
PEG conjugates of RNase 1 were tested for their ability to suppress
the growth of human tumors implanted into the flanks of athymic
mice. The A549 lung tumor cell line was selected for its ability to pro-
liferate in mice, low rate of spontaneous regression, and clinical rele-
vancy. Moreover, A549 cells had been shown previously to be more
refractory than other lines to ribonucleases in vitro [28]. These cells
were grown in Dulbecco’s modified Eagle’s medium containing FBS
(10% vol/vol). Xenograft models were created by implanting 3.27 ×
106 cells into the right rear flank of 43 five- to six-week-old male
athymic (nu/nu) mice. These animals were used in the treatment
group (five mice/conjugate × three conjugates/dose × two doses), posi-
tive control (erlotinib; seven mice), and negative control (vehicle = PBS;
six mice). Tumors were allowed to grow to an average size of ∼75 mm3
before initiation of treatment. All treatments were administered by
intraperitoneal injection of a volume based on the body weight of
the animal (10 μl/g). The mass of the PEG conjugate that was used
to calculate the administered dose included the mass of both the ribo-
nuclease and the pendant PEG. Tumor size was measured twice weekly
using calipers, and percent tumor growth inhibition (%TGI) was
calculated as described previously [11]. Mice were weighed to reveal
severe off-target effects.
Pharmacokinetic Studies
Ribonucleolytic activity remaining in the serum of CD-1 mice was
used to assess the pharmacokinetic profile of PEGylated ribonucleases.
The method was similar to one reported previously [35], except for the
assay used to quantify ribonucleolytic activity [22].
Results and Discussion
A pendant PEG moiety can confer clinical benefit to several small
human proteins, including human growth hormone (Somavert),
erythropoietin (Micera), and interferons α2a (Pegasys) and α2b
(Pegintron) [15]. All extant PEGylated drugs, however, act on extra-
cellular targets. Manifesting the cytotoxic activity of RNase 1 requires
its entry into the cytosol. Thus, for our intent, a pendant PEG moiety
could be a “double-edged sword” [36]. The increased hydrodynamic
volume imposed by the PEG could enhance persistence in circula-
tion but also hinder the traversal of a lipid bilayer, which is necessary
for entry into the cytosol. To probe this dichotomy, we elaborated
the G89C variant of RNase 1 with pendant PEGs of different size
(Figure 1) and assessed the attributes of the ensuing conjugates both
in vitro and in vivo.
Attributes of RNase 1–PEG Conjugates In Vitro
A pendant PEG increased the viscosity radius of a ribonuclease (Fig-
ure 2). As expected, the viscosity radius correlated with the molecular
mass of the PEG moiety: 5 kDa < 20 kDa < 60 kDa.
A small or large PEG moiety at residue 89 had a negligible effect on the
ability of RNase 1 to catalyze the cleavage of 6-FAM-dArUdAdA-6-TAMRA
Figure 2. Size exclusion chromatographic profile of RNase 1–PEG
conjugates. The values within each peak refer to the calculated
viscosity radius [40].
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(Table 1). Apparently, this distal location does not impede the sub-
strate from gaining access to the active site (Figure 1B). Yet, RI retained
notable affinity for the RNase 1–PEG conjugates (Table 1). This
sensitivity is likely a result of the extremely high affinity of RI for
wild-type RNase 1 [8], as well as the orientation of the side chain of
residue 89. Although this residue is at the RI–RNase 1 interface [23],
its side chain is oriented nearly perpendicular to the major plane of the
RI molecule (Figure 1B).
The RNase 1–PEG conjugates had no discernable effect on the
proliferation of K-562 cells in vitro (Table 1 and Figure 3). Likewise,
the RNase 1–PEG conjugates had no effect on the proliferation of
A549 cells in vitro (data not shown). These data are consistent with
a detrimental effect of PEG on membrane translocation, along with
the residual affinity for RI, which is known to suppress cytotoxic
activity in vitro [7,8].
Efficacy of RNase 1–PEG Conjugates in a Xenograft Model
The three RNase 1–PEG conjugates inhibited the growth of solid
human tumors in a mouse xenograft model (Figure 4). Tumor growth
inhibition by RNase 1–PEG conjugates was more pronounced at a
higher dose and for conjugates with larger PEG moieties (Figure 5).
More specifically, values of %TGI correlated with those of viscosity
radii (cf. Figures 2 and 5). The enhanced efficacy of the larger con-
jugates is attributable to their longer persistence in circulation, which
is known to correlate with PEG molecular mass [38]. Our pharmaco-
kinetic analyses are consistent with this explanation—larger PEG
moieties did indeed increase the persistence of a conjugate in serum
(Figure 6). The increased persistence is likely due to a decreased rate
of glomerular filtration [39,40].
The ability of the larger conjugates to inhibit tumor growth is even
greater than suggested by the data depicted in Figure 4. The indicated
Figure 3. Effect of PEGylated variants of RNase 1 on the proliferation
of K-562 cells. The incorporation of [methyl-3H]thymidine into cel-
lular DNA was used to monitor the proliferation of K-562 cells in
the presence of ribonucleases. Data are the mean (±SE) from at
least three separate experiments carried out in triplicate.
Figure 4. Effect of PEGylated variants of RNase 1 on the tumor
volume and body weight (insets) of nu/nu mice with xenograft
models of human A549 lung tumors. Data are the mean (±SE) for
n animals. (A) Low dose (7.5 mg/kg per week). (B) High dose
(75 mg/kg per week). Data for vehicle- and erlotinib-treated animals
are shown in both panels.
Figure 5. Effect of PEGylated variants of RNase 1 on tumor growth
inhibition (%TGI) of nu/nu mice with xenograft models of human
A549 lung tumors. Values are from day 79 (Figure 4).
Table 1. Attributes of RNase 1–PEG Conjugates In Vitro.
Ribonuclease kcat/KM (10
7 M−1 s−1)* K d (nM)
† IC50 (μM)
‡
Wild-type RNase 1 2.9 ± 0.1 2.9 × 10−7 >25
5-kDa mPEG–G89C RNase 1 2.6 ± 0.3 <1.4 >50
20-kDa mPEG–G89C RNase 1 6.8 ± 0.1 <1.4 >50
60-kDa mPEG2–G89C RNase 1 6.1 ± 0.3 <1.4 >50
ONC 0.0018 ± 0.00005 150 ± 50 0.22 ± 0.01
*Values of kcat/KM (±SE) are for the catalysis of 6-FAM-dArU(dA)2-6-TAMRA cleavage at room
temperature in 0.10 M MES-NaOH buffer (pH 6.0) containing NaCl (0.10 M). The values for
RNase 1 and ONC were reported previously [11].
†Values of K d (±SE) are for the complex with human RI at room temperature. The values for
wild-type RNase 1 [8] and ONC [37] were reported previously.
‡Values of IC50 (±SE) are for the incorporation of [methyl-
3H]thymidine into the DNA of K-562
cells. Data are from Figure 3.
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dose (7.5 or 75 mg/kg) includes the mass of the polymer. Because the
molecular mass of RNase 1 is 14.6 kDa, a weekly 7.5 mg/kg dose
of the 5-, 20-, or 60-kDa PEG conjugate corresponds to only 383,
217, or 101 nmol/kg, respectively. Thus, mice at a particular dosing
level received nearly four-fold as many molecules of the 5-kDa PEG
conjugate than the 60-kDa PEG conjugate.
Considering the dosage in molecular rather than mass terms also
highlights an advantage of using an enzymatic catalyst as a drug, a few
molecules can have a large effect. A weekly dose of 7.5 mg/kg of the
60-kDa PEG conjugate inhibited the growth of tumors at a level in-
distinguishable from that of a biweekly dose of 100 mg/kg erlotinib
(Figure 4A). This tyrosine kinase inhibitor was approved in 2004 for
the treatment of non–small cell lung cancer [41]. Because erlotinib
hydrochloride has a molecular mass of 429.90 Da, treated mice received
0.47 mmol/kg each week. Hence, we estimate that 60-kDa mPEG2–
G89C RNase 1 is approximately (0.47 mmol/kg)/(101 nmol/kg) =
5 × 103-fold more efficacious than erlotinib. We are not aware of any
other human protein that can be endowed with such a high level of
preclinical utility by modifying a single amino acid residue.
None of the RNase 1–PEG conjugates exhibited systemic toxicity to
the animals as evidenced by their maintenance of body weight through-
out the duration of the studies (Figure 5, insets). These data indicate
that the toxicity of the RNase 1–PEG conjugates toward neoplastic
cells is selective in vivo.
Basis for the Therapeutic Index of RNase 1–PEG Conjugates
RNase 1 conjugated to human antibody fragments that are directed
against tumor-associated antigens has shown promise in preclinical
studies [42–44]. In those conjugates, specificity derives largely from
the antibody fragment, which is also likely to enhance pharmaco-
kinetics. What is the basis for the favorable therapeutic index demon-
strated by the RNase 1–PEG conjugates (Figure 5)?
To date, two contributing factors have been implicated for the cancer
cell selectivity of RNase 1 and its homologs in vitro. First, cancer cells
are more anionic than comparable noncancerous cells [45–47]. Ac-
cordingly, Coulomb’s law increases preferentially their uptake of highly
cationic molecules, such as RNase 1–PEG conjugates [9,48]. Second,
cancer cells have an enhanced rate of endocytosis [49] and could take
up RNase 1–PEG conjugates more rapidly than do noncancerous cells.
An additional factor is likely to contribute to the favorable thera-
peutic index of the RNase 1–PEG conjugates in vivo. The enhanced
permeability and retention effect is a universal characteristic of solid
tumors [50,51]. Some of the unique aspects of tumor physiology that
contribute to the enhanced permeability and retention effect are the in-
creased permeability of tumor vasculature as well as the poor lymphatic
drainage of tumor tissues. The ensuing diminished plasma clearance of
macromolecules could combine with architectural differences between
normal and neoplastic tissues to accumulate RNase 1–PEG conjugates
near tumors. In addition, the large size of the conjugates could extend
their retention in tumor tissue, as in circulation (Figure 6).
Conclusions
The site-specific conjugation of a PEG moiety is a promising strategy
for the development of cancer chemotherapeutic agents based on
RNase 1. Attaching a PEG moiety to residue 89 of RNase 1 preserves
catalytic activity, and the ensuing RNase 1–PEG conjugates exhibit
marked activity for inhibiting the growth of tumors in xenograft
mouse models without detectable systemic toxicity. The antitumoral
activity of these conjugates in vivo as well as their persistence in
circulation increases with PEG size, consistent with the passive ac-
cumulation in solid tumors as a key to efficacy. This work provides
validation for PEGylated human pancreatic ribonucleases as cancer
chemotherapeutic agents.
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